Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NBE-002 |
Synonyms | |
Therapy Description |
NBE-002 is a next-generation antibody drug conjugate consisting of a humanized monoclonal antibody directed against the receptor tyrosine kinase ROR1, site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, potentially leading to inhibition of DNA replication and repair and may inhibit tumor cell proliferation and survival (Cancer Research, 79(13), LB-197, doi: 10.1158/1538-7445.AM2019-LB-197). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NBE-002 | NBE002|NBE 002|iADC NBE-002|Anti-ROR1/PNU-159682 Derivative ADC NBE-002 | ROR1 Antibody 7 | NBE-002 is a next-generation antibody drug conjugate consisting of a humanized monoclonal antibody directed against the receptor tyrosine kinase ROR1, site-specifically conjugated to a derivative of the highly potent anthracycline PNU-159682, potentially leading to inhibition of DNA replication and repair and may inhibit tumor cell proliferation and survival (Cancer Research, 79(13), LB-197, doi: 10.1158/1538-7445.AM2019-LB-197). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04441099 | Phase Ib/II | NBE-002 | NBE-002 in Patients With Advanced Solid Tumors | Terminated | USA | 0 |